Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 22:8:107-121.
doi: 10.2147/JBM.S102328. eCollection 2017.

New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib

Paul G Richardson  1 , Shaji Kumar  2 , Jacob P Laubach  1 , Claudia Paba-Prada  1 , Neeraj Gupta  3 , Deborah Berg  3 , Helgi van de Velde  3 , Philippe Moreau  4
Affiliations
Review

New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib

Paul G Richardson et al. J Blood Med. .

Abstract

Ixazomib is the first oral proteasome inhibitor to be approved, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was on the basis of results from the phase 3, double-blind, placebo-controlled TOURMALINE-MM1 study, which demonstrated a 35% improvement in progression-free survival with the all-oral combination of ixazomib plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone alone (median: 20.6 vs 14.7 months; hazard ratio: 0.74, p=0.012; median follow-up 14.7 months). The addition of ixazomib to the lenalidomide-dexamethasone regimen was associated with limited additional toxicity and had no adverse impact on patient-reported quality of life. Common grade ≥3 adverse events with ixazomib include gastrointestinal adverse events, rash, and thrombocytopenia. Here, we review the efficacy, safety, pharmacokinetics, and patient-reported quality of life data seen with ixazomib, and discuss the role of this oral agent in the treatment of patients with relapsed/refractory multiple myeloma, including in patients with high-risk cytogenetic abnormalities and those with multiple prior therapies.

Keywords: clinical; efficacy; ixazomib; multiple myeloma; pharmacokinetics; proteasome inhibitor; tolerability.

PubMed Disclaimer

Conflict of interest statement

Disclosure PGR: Membership on an entity’s board of directors, speakers bureau, or its advisory committees: Takeda, Janssen. SK: Consultancy: Takeda, Celgene, Janssen, BMS, Noxxon, Kesios, Glycomimetics, Skyline; honoraria, Skyline Dx. JPL: Consultancy: Takeda and Novartis; research funding: Takeda, Novartis, Celgene. NG, DB, and HvdV: Employment: Takeda Pharmaceutical Company Limited. PM: Honoraria, BMS, Takeda, Janssen, Celgene, Novartis. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Kaplan–Meier analysis of PFS in the TOURMALINE-MM1 study on the intent-to-treat population (A) and by prespecified patient subgroups (B) (data from final statistical analysis for progression-free survival). Notes: From New England Journal of Medicine, Moreau P, Masszi T, Grzasko N, et al., Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma, 374., 1621. Copyright © 2016 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Abbreviations: CI, confidence interval; HR, hazard ratio; mo, month; NE, not estimable; PFS, progression-free survival.
See this image and copyright information in PMC

References

    1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–1060. - PubMed
    1. Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet. 2015;385:2197–2208. - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. - PubMed
    1. International Agency for Research on Cancer GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. 2012. [Accessed December 13, 2016]. Available from: http://globocan.iarc.fr/Default.aspx.
    1. Anderson KC. Oncogenomics to target myeloma in the bone marrow microenvironment. Clin Cancer Res. 2011;17:1225–1233. - PubMed

LinkOut - more resources